Michael Edward Szperka

Array ( [id] => 18295523 [patent_doc_number] => 20230105209 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-04-06 [patent_title] => ANTIBODY SPECIFIC TO SPIKE PROTEIN OF SARS-COV-2 AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/937744 [patent_app_country] => US [patent_app_date] => 2022-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9421 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17937744 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18932304 [patent_doc_number] => 11884711 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Fusion proteins of GDF15 and use thereof [patent_app_type] => utility [patent_app_number] => 17/935134 [patent_app_country] => US [patent_app_date] => 2022-09-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 11 [patent_no_of_words] => 17547 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 106 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17935134 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18582912 [patent_doc_number] => 20230265169 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-24 [patent_title] => MONOCLONAL ANTIBODY FOR SPIKE PROTEIN OF MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS, AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 17/952308 [patent_app_country] => US [patent_app_date] => 2022-09-25 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11809 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -4 [patent_words_short_claim] => 167 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17952308 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18468893 [patent_doc_number] => 20230203176 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-06-29 [patent_title] => Methods For Prevention Of Graft Rejection In Xenotransplantation [patent_app_type] => utility [patent_app_number] => 17/946917 [patent_app_country] => US [patent_app_date] => 2022-09-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 38821 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17946917 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20077597 [patent_doc_number] => 12351647 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-07-08 [patent_title] => Binding agent and assay for PIVKA [patent_app_type] => utility [patent_app_number] => 17/821937 [patent_app_country] => US [patent_app_date] => 2022-08-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 15710 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 242 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17821937 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18597264 [patent_doc_number] => 20230272059 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-08-31 [patent_title] => ANTI-TNF-ALPHA-ANTIBODIES AND FUNCTIONAL FRAGMENTS THEREOF [patent_app_type] => utility [patent_app_number] => 17/890857 [patent_app_country] => US [patent_app_date] => 2022-08-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 26143 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 348 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17890857 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18141449 [patent_doc_number] => 20230015291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => DNASE FUSION POLYPEPTIDES AND RELATED COMPOSITIONS AND METHODS [patent_app_type] => utility [patent_app_number] => 17/819006 [patent_app_country] => US [patent_app_date] => 2022-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 51959 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 58 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17819006 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19738349 [patent_doc_number] => 12215167 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-02-04 [patent_title] => Anti-tissue factor antibodies, antibody-drug conjugates, and related methods [patent_app_type] => utility [patent_app_number] => 17/877853 [patent_app_country] => US [patent_app_date] => 2022-07-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 47 [patent_figures_cnt] => 88 [patent_no_of_words] => 107500 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 93 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17877853 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19731132 [patent_doc_number] => 12209123 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2025-01-28 [patent_title] => Antibodies to Feline McDonough Sarcoma (FMS)-like tyrosine kinase 3 receptor ligand (FLT3L) and uses thereof for treating autoimmune and inflammatory diseases [patent_app_type] => utility [patent_app_number] => 17/814075 [patent_app_country] => US [patent_app_date] => 2022-07-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 31 [patent_figures_cnt] => 68 [patent_no_of_words] => 26148 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 65 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17814075 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18228932 [patent_doc_number] => 20230067926 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-03-02 [patent_title] => SYSTEMS AND METHODS FOR MONITORING PLATELET ACTIVATION [patent_app_type] => utility [patent_app_number] => 17/868422 [patent_app_country] => US [patent_app_date] => 2022-07-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5996 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17868422 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18077402 [patent_doc_number] => 20220403014 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-22 [patent_title] => COMPOSITIONS AND METHODS OF TREATING THROMBOSIS [patent_app_type] => utility [patent_app_number] => 17/846697 [patent_app_country] => US [patent_app_date] => 2022-06-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18925 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17846697 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18141339 [patent_doc_number] => 20230015181 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-19 [patent_title] => Antibodies to Plasminogen Activator Inhibitor-1 (PAI-1) and Uses Thereof [patent_app_type] => utility [patent_app_number] => 17/843777 [patent_app_country] => US [patent_app_date] => 2022-06-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 46513 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17843777 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18207374 [patent_doc_number] => 20230053631 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-02-23 [patent_title] => ANTIBODIES TO LILRB2 [patent_app_type] => utility [patent_app_number] => 17/838426 [patent_app_country] => US [patent_app_date] => 2022-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 49402 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17838426 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17990198 [patent_doc_number] => 20220356235 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-11-10 [patent_title] => FACTOR H POTENTIATING ANTIBODIES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/829688 [patent_app_country] => US [patent_app_date] => 2022-06-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21917 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17829688 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18125821 [patent_doc_number] => 20230011438 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-01-12 [patent_title] => CHIMERIC FACTOR VIII POLYPEPTIDES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/826932 [patent_app_country] => US [patent_app_date] => 2022-05-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 61044 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -3 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17826932 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18094655 [patent_doc_number] => 20220412996 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-12-29 [patent_title] => BLOOD FACTOR MONITORING ASSAY AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 17/749834 [patent_app_country] => US [patent_app_date] => 2022-05-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30765 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17749834 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19692902 [patent_doc_number] => 20250011447 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2025-01-09 [patent_title] => BISPECIFIC ANTIBODY BINDING TO BCMA AND CD3, AND PREPARATION METHOD THEREFOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 18/256316 [patent_app_country] => US [patent_app_date] => 2022-05-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12589 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18256316 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17734764 [patent_doc_number] => 20220220223 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-07-14 [patent_title] => TREATMENT OF ALLERGIC DISEASES WITH CHIMERIC PROTEIN [patent_app_type] => utility [patent_app_number] => 17/711517 [patent_app_country] => US [patent_app_date] => 2022-04-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19747 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 111 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17711517 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19521138 [patent_doc_number] => 12122847 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-10-22 [patent_title] => Factor VII (FVII(a))/TREM-like transcript 1 (TLT-1) bispecific antibodies [patent_app_type] => utility [patent_app_number] => 17/699460 [patent_app_country] => US [patent_app_date] => 2022-03-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31264 [patent_no_of_claims] => 6 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 263 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17699460 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17851916 [patent_doc_number] => 20220281958 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2022-09-08 [patent_title] => HUMAN MONOCLONAL ANTIBODIES TO SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 (SARS-CoV-2) [patent_app_type] => utility [patent_app_number] => 17/655503 [patent_app_country] => US [patent_app_date] => 2022-03-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 60524 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17655503 [rel_patent_id] =>[rel_patent_doc_number] =>)